Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NYSE - Nasdaq Real Time Price USD

Thermo Fisher Scientific Inc. (TMO)

Compare
535.55
+3.00
+(0.56%)
At close: February 24 at 4:00:02 PM EST
529.96
-5.59
(-1.04%)
Pre-Market: 9:13:34 AM EST
Loading Chart for TMO
DELL
  • Previous Close 532.55
  • Open 531.81
  • Bid 517.39 x 900
  • Ask 550.00 x 900
  • Day's Range 531.81 - 543.62
  • 52 Week Range 493.30 - 627.88
  • Volume 1,375,343
  • Avg. Volume 2,016,322
  • Market Cap (intraday) 202.042B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 32.36
  • EPS (TTM) 16.55
  • Earnings Date Apr 22, 2025 - Apr 28, 2025
  • Forward Dividend & Yield 1.72 (0.32%)
  • Ex-Dividend Date Mar 14, 2025
  • 1y Target Est 664.26

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

125,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMO

View More

Performance Overview: TMO

Trailing total returns as of 2/24/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMO
2.94%
S&P 500
1.73%

1-Year Return

TMO
4.91%
S&P 500
17.58%

3-Year Return

TMO
0.10%
S&P 500
39.51%

5-Year Return

TMO
67.73%
S&P 500
85.48%

Compare To: TMO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMO

View More

Valuation Measures

As of 2/24/2025
  • Market Cap

    202.04B

  • Enterprise Value

    227.75B

  • Trailing P/E

    32.40

  • Forward P/E

    22.99

  • PEG Ratio (5yr expected)

    2.07

  • Price/Sales (ttm)

    4.78

  • Price/Book (mrq)

    4.07

  • Enterprise Value/Revenue

    5.31

  • Enterprise Value/EBITDA

    19.74

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.77%

  • Return on Assets (ttm)

    4.89%

  • Return on Equity (ttm)

    13.13%

  • Revenue (ttm)

    42.88B

  • Net Income Avi to Common (ttm)

    6.34B

  • Diluted EPS (ttm)

    16.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.57B

  • Total Debt/Equity (mrq)

    65.98%

  • Levered Free Cash Flow (ttm)

    6.59B

Research Analysis: TMO

View More

People Also Watch